POLBF (Poolbeg Pharma) Total Equity: $11.51 Mil (As of Dec. 2025)


What is Poolbeg Pharma Total Equity?

Poolbeg Pharma POLBF -20.36% Total Equity is $11.51 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's total equity for the quarter that ended in Dec. 2025 was $11.51 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Poolbeg Pharma Total Equity Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Total Equity Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
30.03 22.32 18.28 11.72 11.51

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only 18.28 15.84 11.72 16.19 11.51

Poolbeg Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Poolbeg Pharma's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=13.309-1.795
=11.51

Poolbeg Pharma's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=13.309-1.795
=11.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $11.51 Mil mean?
Poolbeg Pharma (POLBF) has a Total Equity of $11.51 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Total Equity too high?
Poolbeg Pharma's current Total Equity is $11.51 Mil.
How does Poolbeg Pharma's Total Equity compare to VRTX and REGN?
Poolbeg Pharma's Total Equity of $11.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Poolbeg Pharma and its competitors. Poolbeg Pharma's current Total Equity is $11.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Total Equity of $11.51 Mil. The current Total Equity is $11.51 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Total Equity is $11.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.